Sponsored message
Logged in as
Audience-funded nonprofit news
radio tower icon laist logo
Next Up:
0:00
0:00
Subscribe
  • Listen Now Playing Listen
News

White House announces new round of drug-price deals

an older man in a dark blue suit with a red tie stands at a microphone and talks while two men and a woman in suits stand behind him and watch
President Donald Trump unveiled deals with nine pharmaceutical companies on drug prices in a White House event Friday.
(
Brendan Smialowski
/
Getty Images
)

One year ago, Congress defunded public media. Now that we're 100% community funded, please become a sustaining member or increase your existing membership today.

President Donald Trump said the administration has reached agreements with nine more drugmakers to bring their U.S. drug prices more in line with what other wealthy countries pay.

Fourteen companies in total have now reached what the administration calls most-favored-nation pricing deals. The companies that took part in Friday's announcement were: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi.

They agreed to charge the U.S. government no more for new drugs than the prices paid by other well-off countries. The agreements will allow state Medicaid programs to access lower prices from the nine companies. In a statement, the White House said the change will result "in billions of dollars in savings."

The drugmakers also agreed to invest at least $150 billion in manufacturing operations in the U.S. The president is seeking to increase domestic production of pharmaceuticals.

In addition, the companies agreed to make some of their most popular drugs available at lower prices to consumers who pay out of pocket through a government website called TrumpRx.com. The TrumpRx website is expected to launch in early 2026, and would take consumers to pharmaceutical companies' direct-to-consumer websites to fulfill orders.

For example, Merck will reduce the price of Januvia, a medication for Type 2 diabetes, from $330 to $100 for patients purchasing directly through TrumpRx, the White House said. Amgen will reduce the price of Repatha, a cholesterol-lowering drug, from $573 to $239 when purchased through TrumpRx.

In exchange for these concessions, the companies will be exempt from possible administration tariffs for three years.

Sponsored message
Trending on LAist

The extent of savings for consumers under the agreements is unclear. Medicaid and its beneficiaries already pay some of the lowest prices for drugs. And people with health insurance could spend less on copays for their medicines than paying cash for them through the drugmakers.

Separately, Trump said during the press event that he would like to get health insurers to lower their prices, too.

"I'm going to call a meeting of the insurance companies," he said. "I'm going to see if they [will] get their price down, to put it very bluntly."

One year ago, Congress voted to defund public media, eliminating a critical $1.7 million from our budget every year going forward. But they couldn’t silence us, and we’re not going anywhere. LAist is now 100% community funded and that means we’re taking our future into our own hands and turning to you to keep local reporting strong.

You come to LAist because you want independent reporting and trustworthy local information. Our nonprofit newsroom doesn’t answer to shareholders looking to turn a profit. Instead, we answer to you and our communities. We are free to follow facts wherever they lead and to hold power to account without fear or favor. Our only loyalty is to our readers and listeners and our mission: to inform, engage, and strengthen Southern California’s communities.

If this story helped you, please become a monthly member today to help sustain this mission. It just takes 1 minute to donate below.
Senior Vice President News, Editor in Chief

Make your tax-deductible donation today